Zhang Shuang, Qin Yu-Ping, Kuang Jiang-Ming, Liu Yi-He
College of Computer Science, Neijiang Normal University, Neijiang, Sichuan, China.
The Engineering & Technical College of Chengdu University of Technology, Leshan, Sichuan, China.
Technol Health Care. 2018;26(1):145-153. doi: 10.3233/THC-171038.
Osteosarcoma, which is also termed osteogenic sarcoma or osteoma sarcomatosum, is the most common form of bone cancer. Typical osteosarcoma can occur at any age, including in infants, children, and the elderly, but more than half of cases occur in individuals who are 10-20 years old.
Here, the objective was to search for protein markers to indicate resistance to cisplatin in osteosarcoma and provide a theoretical basis for the early and accurate use of cisplatin to treat osteosarcoma.
Thirty patients with osteosarcoma were selected for the study. Experimental studies on the chemosensitivity of osteosarcoma using an in vitro kit method were performed, and cisplatin-resistant and cisplatin-sensitive osteosarcoma tissues were obtained. A representative sample was chosen to analyze and identify differentially expressed proteins in cisplatin-resistant tissues.
The osteosarcoma-sensitive tissue was analyzed using 2-D electrophoresis and time-of-flight mass spectrometry. Differently expressed proteins were analyzed by western blotting to identify markers. Cisplatin-resistant and cisplatin-sensitive osteosarcoma tissues were obtained. Five significantly differentially expressed proteins were identified, including ALDOA and PGK1.
The results indicate that ALDOA and PGK1 might be appropriate markers that can be used when treating osteosarcoma with cisplatin.
骨肉瘤，也称为成骨肉瘤或骨瘤肉瘤，是最常见的骨癌形式。典型的骨肉瘤可发生于任何年龄，包括婴儿、儿童和老年人，但超过半数的病例发生在10至20岁的个体中。
本研究旨在寻找骨肉瘤中顺铂耐药的蛋白质标志物，为早期、准确应用顺铂治疗骨肉瘤提供理论依据。
选取30例骨肉瘤患者进行研究。采用体外试剂盒法对骨肉瘤的化疗敏感性进行实验研究，获取顺铂耐药和敏感的骨肉瘤组织。选取代表性样本分析鉴定顺铂耐药组织中差异表达的蛋白质。
利用二维电泳和飞行时间质谱分析骨肉瘤敏感组织。通过蛋白质免疫印迹分析差异表达的蛋白质以鉴定标志物。获得了顺铂耐药和敏感的骨肉瘤组织。鉴定出5种显著差异表达的蛋白质，包括醛缩酶A（ALDOA）和磷酸甘油酸激酶1（PGK1）。
结果表明，ALDOA和PGK1可能是顺铂治疗骨肉瘤时可用的合适标志物。
